Evidence map›Paper›PMID 41488889›Full record

Trial reportBlood neoplasia2026

Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML.

Jayanshu Jain, Kelly Pugh, Shivani Handa, Kaitlyn M Dvorak-Kornaus, Qiuhong Zhao, Roland B Walter, Rachel Cook, Jennifer Saultz, Ronan Swords, Junyang Li and 12 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jayanshu JainDivision of Hematology, The Ohio State University, Columbus, OH.
Kelly PughDivision of Hematology, The Ohio State University, Columbus, OH.
Shivani HandaDivision of Hematology, The Ohio State University, Columbus, OH.
Kaitlyn M Dvorak-KornausDivision of Hematology, The Ohio State University, Columbus, OH.
Qiuhong ZhaoDivision of Hematology, The Ohio State University, Columbus, OH.
Roland B WalterTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.
Rachel CookDivision of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR.
Jennifer SaultzDivision of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR.
Ronan SwordsDivision of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR.
Junyang LiTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.
George S LaszloTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.
Nicole R GrieselhuberDivision of Hematology, The Ohio State University, Columbus, OH.
Alice S MimsDivision of Hematology, The Ohio State University, Columbus, OH.
Karilyn T M LarkinDivision of Hematology, The Ohio State University, Columbus, OH.
Kieran SahasrabudheDivision of Hematology, University of Wisconsin, Madison, WI.
James S BlachlyDivision of Hematology, The Ohio State University, Columbus, OH.
Gregory K BehbehaniDivision of Hematology, The Ohio State University, Columbus, OH.
Ann-Kathrin EisfeldDivision of Hematology, The Ohio State University, Columbus, OH.
Meixiao LongDivision of Hematology, The Ohio State University, Columbus, OH.
Andrew SrisuwananukornDivision of Hematology, The Ohio State University, Columbus, OH.
Kristin L KoenigDivision of Hematology, The Ohio State University, Columbus, OH.
Uma BorateDivision of Hematology, The Ohio State University, Columbus, OH.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This phase 1 study investigated the addition of gemtuzumab ozogamicin (GO) to intensive chemotherapy with cytarabine, daunorubicin, and midostaurin in 21 patients with newly diagnosed (ND) FMS-like tyrosine kinase 3 (

Identifiers

PMID41488889
PMCPMC12756534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.